Presentation: Next-Generation DNA NanoVectors – an alternative Vector Platform for the safe, rapid and persistent manufacture of recombinant T cells for Autologous T Cell Immunotherapy

This presentation was given during the ICLE – International Conference for Lymphocyte Engineering March, 2022.

Gene Delivery was improving but expression from Non-Viral Vectors was still transient

Download Presentation

a slide from Dr Richard Harbottle's presentation.



Dr. Richard Harbottle

Head of DNA Vector Research, German Cancer Research Centre (DKFZ) – Heidelberg, Germany

Stanford Center for Cancer, Cell Therapy Stanford Cancer Institute
Stanford University

Dr Richard Harbottle undertook his undergraduate degree in Scotland at the University of St Andrews and his MSc, PhD and post-doctoral training in a Gene Therapy lab at Imperial College London where he worked on developing non-viral methods for introducing DNA into cells. He is currently the Research Group Leader of the DNA Vector Laboratory at the German Cancer Research Centre (DKFZ) in Heidelberg. His lab is now focused on the generation and application of novel, next-generation DNA vectors for gene therapy and cell therapy and for the safe and persistent genetic modification of cells. These DNA vectors provide therapeutic transgene expression without the use of potentially toxic viral components or the risk of insertional mutagenesis.